News
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
The immediate market reaction to Novo Nordisk's earnings report was a positive one. As of 7 a.m. EDT, a few hours after the earnings release, shares of the drugmaker were up by about 5%. In short, the ...
Entering the first full trading hour of Wednesday's session, Madison Mills monitors several of the day's developing market ...
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback